Individuals Discontinuing Anti-Obesity Medications Put On Weight Four Times Faster Compared to Those on Conventional Diets
New research reveals that patients who come off blockbuster weight-loss injections like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who halt conventional lifestyle plans.
Research printed in a leading medical journal points out that while obese individuals often shed substantial amounts of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Individuals using these treatments should be aware of the potential of rapid rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass in about a year and a half.
Weighing Approaches
The study, which reviewed dozens of studies involving thousands of participants, compared the outcomes of these new drugs with other pills.
Scientists emphasize that people who lose weight through lifestyle changes alone generally have a slower creep back—perhaps 100 grams monthly—after stopping.
Explaining the Fast Rebound
Nutrition scientists believe the way of the injections explains the accelerated regain.
These medications copy a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
Medical guidelines recommend the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the high risk of weight regain, the therapy is often life-long.
This view is echoed by pharmaceutical companies, who note that the results "underscore the persistent nature of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the jabs explain a intense resurgence of cravings.
"It felt as if a switch activating and you become ravenous," recalled a patient.
The struggle is worsened if users have not developed permanent dietary or behavioural modifications during treatment.
Significant Adoption
Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and lasting health benefits likely depends on combined behavioural support.
